Verastem VSTM Stock
Verastem Price Chart
Verastem VSTM Financial and Trading Overview
Verastem stock price | 5.7 USD |
Previous Close | 9.32 USD |
Open | 11.12 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 900 |
Day's Range | 10 - 12 USD |
52 Week Range | 3.48 - 17.52 USD |
Volume | 723.05K USD |
Avg. Volume | 244.67K USD |
Market Cap | 181.12M USD |
Beta (5Y Monthly) | 0.70176 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.66 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 39 USD |
VSTM Valuation Measures
Enterprise Value | 137.51M USD |
Trailing P/E | N/A |
Forward P/E | -2.426009 |
PEG Ratio (5 yr expected) | -1.53 |
Price/Sales (ttm) | Infinity |
Price/Book (mrq) | 5.484034 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -1.829 |
Trading Information
Verastem Stock Price History
Beta (5Y Monthly) | 0.70176 |
52-Week Change | -18.030% |
S&P500 52-Week Change | 20.43% |
52 Week High | 17.52 USD |
52 Week Low | 3.48 USD |
50-Day Moving Average | 6.7 USD |
200-Day Moving Average | 6.76 USD |
VSTM Share Statistics
Avg. Volume (3 month) | 244.67K USD |
Avg. Daily Volume (10-Days) | 289.72K USD |
Shares Outstanding | 16.74M |
Float | 11.52M |
Short Ratio | 0.45 |
% Held by Insiders | N/A |
% Held by Institutions | N/A |
Shares Short | 221.1K |
Short % of Float | 1.54% |
Short % of Shares Outstanding | 1.32% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -39.71% |
Return on Equity (ttm) | -114.31% |
Income Statement
Revenue (ttm) | 0 USD |
Revenue Per Share (ttm) | 0 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 2.6M USD |
EBITDA | -75183000 USD |
Net Income Avi to Common (ttm) | -72564000 USD |
Diluted EPS (ttm) | -4.87 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 111.2M USD |
Total Cash Per Share (mrq) | 6.64 USD |
Total Debt (mrq) | 46.45M USD |
Total Debt/Equity (mrq) | 85.73 USD |
Current Ratio (mrq) | 5.317 |
Book Value Per Share (mrq) | 1.973 |
Cash Flow Statement
Operating Cash Flow (ttm) | -64678000 USD |
Levered Free Cash Flow (ttm) | -39258376 USD |
Profile of Verastem
Country | United States |
State | MA |
City | Needham |
Address | 117 Kendrick Street |
ZIP | 02494 |
Phone | 781 292 4200 |
Website | https://www.verastem.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 57 |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Q&A For Verastem Stock
What is a current VSTM stock price?
Verastem VSTM stock price today per share is 5.7 USD.
How to purchase Verastem stock?
You can buy VSTM shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Verastem?
The stock symbol or ticker of Verastem is VSTM.
Which industry does the Verastem company belong to?
The Verastem industry is Biotechnology.
How many shares does Verastem have in circulation?
The max supply of Verastem shares is 51.49M.
What is Verastem Price to Earnings Ratio (PE Ratio)?
Verastem PE Ratio is now.
What was Verastem earnings per share over the trailing 12 months (TTM)?
Verastem EPS is -3.66 USD over the trailing 12 months.
Which sector does the Verastem company belong to?
The Verastem sector is Healthcare.
Verastem VSTM included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 20257.83 USD — |
-5.96
|
— — | 20236.33 USD — | 20672.41 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
- {{ link.label }} {{link}}